Phase I study of tremelimumab (CP-675 206) plus PF-3512676 (CPG 7909) in patients with melanoma or advanced solid tumours

BACKGROUND: Tremelimumab, a fully human cytotoxic T-lymphocyte antigen 4 monoclonal antibody, and PF-3512676, a Toll-like receptor-9 agonist, are targeted immune modulators that elicit durable single-agent antitumour activity in advanced cancer. METHODS: To determine the maximum tolerated dose (MTD)...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Millward, M, Underhill, C, Lobb, S, McBurnie, J, Meech, S J, Gomez-Navarro, J, Marshall, M A, Huang, B, Mather, C B
Formato: Artigo
Idioma:Inglês
Publicado em: Nature Publishing Group 2013
Assuntos:
Clinical Study
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3670507/
https://ncbi.nlm.nih.gov/pubmed/23652314
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bjc.2013.227
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados